A University of Minnesota research team was awarded an R01 grant for their project, which aims to develop a profile analysis of oral cell DNA that may predict head and neck squamous cell carcinoma susceptibility in smokers and assess the role of alcohol intake.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
